Harrow Executed A Five-year Strategic Supply And Development Agreement For FDA-approved Triesence, A Preservative-free Synthetic Corticosteroid For Visualization During Vitrectomy And The Treatment Of Ocular Inflammatory Conditions That Are Unresponsive T